Melanie Bergman, MD
Gynecologic Oncology · Spokane, WANPI 1902892987
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $848 of the $967 with a category attached, or 87.6%. 9 manufacturers reported payments, led by Intuitive Surgical at 45.6% of the total. Reporting peaked in 2019 at $244 and has fallen 82.2% since, to $43 in 2025.
Across 14 payments — averaging $69.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$441
- Seagen Inc.$125
- GSK$115
- Foundation Medicine, Inc.$102
- AstraZeneca$93
- Coherus Oncology, Inc.$27
- plus $64 from 3 others
Across 157 payments — averaging $5877.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$418K
- GSK$249K
- Genmab U.S., Inc.$125K
- Astrazeneca UK Limited$98K
- E.r. Squibb & Sons, L.L.C.$31K
- Bristol Myers Squibb$1K
What the payments were for
- Speaking & faculty fees$10211%
- Food & beverage$84888%
- Gifts$172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $441 |
| Seagen Inc. | 1 | $125 |
| GSK | 1 | $115 |
| Foundation Medicine, Inc. | 1 | $102 |
| AstraZeneca | 1 | $93 |
| Coherus Oncology, Inc. | 1 | $27 |
| Davol Inc. | 1 | $27 |
| Merck | 1 | $21 |
| Caris MPI, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$256
- TIVDAK$125
- ZEJULA$115
- FOUNDATIONONE$102
- FOUNDATIONONE HEME$102
- FOUNDATIONONE CDX$102
- FOUNDATIONFOCUS$102
- FOUNDATIONONE LIQUID$102
How this compares
$967 in reported general payments places this provider in the 55th percentile of 36 gynecologic oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 14 | $7,997 |
| Estradiol | 16 | $816 |
| Oxycodone Hcl | 35 | $636 |
| Megestrol Acetate | 20 | $369 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 44 | $271 |
| Letrozole | 13 | $193 |
| Ondansetron OdtOndansetron | 13 | $170 |
| Ondansetron Hcl | 18 | $60 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Spokane
- Elizabeth GrosenSpokane$3K
- Susannah MourtonSpokane$778
- Casey HaySpokane$526
- Chirag ShahSeattle$732K
- Fernanda MusaSeattle$120K
- Bobbie RimelSeattle$41K
- Nicole FlemingSeattle$20K
- Kristin TaylorEverett$12K
- Renata UrbanSeattle$7K
- Robert OreLacey$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.